SAN FRANCISCO — In topline results of a phase 1/2 trial of PAN-90806 presented at the Ophthalmology Innovation Summit at the American Academy of Ophthalmology meeting, PanOptica cited finding a biological response for the once-daily anti-VEGF topical eye drop formulation.
The double-masked, dose-ranging trial randomized 51 treatment-naive patients with wet AMD to receive three dose strengths of PAN-90806 monotherapy over a 12-week period.
The study showed 88% of patients who completed the study experienced either clinical improvement or stability of their disease. Drug safety was
Uncategorized